NCT03447756 is a Phase 1 clinical trial of ABX-1431 in Post Herpetic Neuralgia, sponsored by Abide Therapeutics.

Who is sponsoring NCT03447756?

NCT03447756 is sponsored by Abide Therapeutics.

What drugs are being tested in NCT03447756?

Interventions in NCT03447756: ABX-1431, Placebo oral capsule.

What condition does NCT03447756 study?

NCT03447756 studies Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy, Small Fiber Neuropathy, Post-Traumatic Neuralgia.

Is NCT03447756 still recruiting?

NCT03447756 is currently completed. Last updated 12 July 2019.

Last reviewed 2019-07-12 · How we verify

NCT03447756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Titration Study of ABX-1431

Completed Phase 1 Last updated 12 July 2019

What this trial tests

Phase 1 trial testing ABX-1431 in Post Herpetic Neuralgia in 39 participants. Completed in 7 May 2019.

Timeline

2 October 2017

Primary endpoint
7 May 2019

7 May 2019

Quick facts

Lead sponsor	Abide Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	39
Start date	2 October 2017
Primary completion	7 May 2019
Estimated completion	7 May 2019
Sites	1 location across Moldova

Drugs / interventions tested

ABX-1431 — full drug profile →
Placebo oral capsule

Conditions studied

Post Herpetic Neuralgia — all drugs for Post Herpetic Neuralgia →
Diabetic Peripheral Neuropathy — all drugs for Diabetic Peripheral Neuropathy →
Small Fiber Neuropathy — all drugs for Small Fiber Neuropathy →
Post-Traumatic Neuralgia — all drugs for Post-Traumatic Neuralgia →

Sponsor

Abide Therapeutics — full company profile →

Who can join

18 and older, any sex, with Post Herpetic Neuralgia or Diabetic Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?
Moreno E, Cavic M, Krivokuca A, Casadó V, et al · · 2019 · cited 95× · PMID 31024307 · DOI 10.3389/fphar.2019.00339
Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain.
Tajti J, Szok D, Csáti A, Szabó Á, et al · · 2023 · cited 47× · PMID 36835524 · DOI 10.3390/ijms24044114
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ, Huestis MA, Amendolara B, Vandrey R, et al · · 2020 · cited 33× · PMID 33086126 · DOI 10.1016/j.pbb.2020.173059
Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective.
Perin P, Mabou Tagne A, Enrico P, Marino F, et al · · 2020 · cited 8× · PMID 33329293 · DOI 10.3389/fneur.2020.505995

Verify or expand the search:

Other trials of ABX-1431

Trials testing the same drug.

NCT03625453 — Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder · Phase 2 · completed
NCT03058562 — A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome · Phase 1 · completed
NCT02875678 — A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia · Phase 1 · terminated

Other Abide Therapeutics trials

Trials by the same sponsor.

NCT03625453 — Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder · Phase 2 · completed
NCT03138421 — Central Pain Study for ABX-1431 · Phase 1 · completed
NCT03058562 — A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome · Phase 1 · completed
NCT02875678 — A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03447756 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abide Therapeutics
Last refreshed: 12 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03447756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing